Parkinson's Disease: Diagnostics and Clinical Trials

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement. This feed focuses on therapeutic aspects, diagnostic tools including medical imaging, and clinical trials in PD.

August 4, 2020
Review

Effectiveness of Physical Therapy Interventions in Reducing Fear of Falling among Individuals with Neurological Diseases: A Systematic Review and Meta-analysis

Archives of Physical Medicine and Rehabilitation
Libak AbouLaura A Rice
August 5, 2020
Open Access

Constituents of Huberantha jenkinsii and Their Biological Activities

Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry
Htoo Tint SanKittisak Likhitwitayawuid
August 4, 2020

The Iron Chelator Deferiprone Improves the Phenotype in a Mouse Model of Tauopathy

Journal of Alzheimer's Disease : JAD
Shalini S RaoPaul A Adlard
August 8, 2020

Double-Blind, Randomized, Placebo-Controlled Trial of DA-9701 in Parkinson's Disease: PASS-GI Study

Movement Disorders : Official Journal of the Movement Disorder Society
Ji-Hyun ChoiHee Tae Kim
August 4, 2020

Image guidance in deep brain stimulation surgery to treat Parkinson's disease: a comprehensive review

IEEE Transactions on Bio-medical Engineering
Yiming XiaoTerry M Peters
August 8, 2020

The transcription factor PITX1 drives astrocyte differentiation by regulating the SOX9 gene

The Journal of Biological Chemistry
Jeong Su ByunBaek-Soo Han
August 11, 2020
Case Report
Open Access

Deep Brain Stimulation Target Selection in Co-Morbid Essential Tremor and Parkinson's Disease

Tremor and Other Hyperkinetic Movements
Anant WadhwaAmar Patel
August 9, 2020

Impaired proteasome activity and neurodegeneration with brain iron accumulation in FBXO7 defect

Annals of Clinical and Translational Neurology
Marta Correa-VelaCarmen Espinós
August 8, 2020
Open Access

Parallel-Channel Electrotaxis and Neuron Screening of Caenorhabditis elegans

Micromachines
Khaled YoussefPouya Rezai
August 4, 2020
Review

Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020

Journal of Parkinson's Disease
Kevin McFarthingSimon R W Stott
August 9, 2020

The accuracy of self-report logbooks of adherence to prescribed home-based exercise in Parkinson's disease

Disability and Rehabilitation
Matthew SchmidtNatalie E Allen
August 7, 2020
Open Access

Feasibility of a Cognitive Training Game in Parkinson's Disease: The Randomized Parkin'Play Study

European Neurology
Sjors C F van de WeijerMark L Kuijf
August 5, 2020
Review

Therapy of Parkinson's Disease Subtypes

Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics
Connie MarrasTiago A Mestre
August 10, 2020
Open Access

Effect of melatonin administration on the PER1 and BMAL1 clock genes in patients with Parkinson's disease

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
D L Delgado-LaraG G Ortiz
August 9, 2020

A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers

Autophagy
Tetsushi KatauraMasaya Imoto
August 7, 2020

Non-motor symptoms in Parkinson´s disease are reduced by nabilone

Annals of Neurology
Marina PeballParkinson´s Disease Working Group Innsbruck

Sign up to follow this feed and discover related papers.

Related Feeds

AFM in situ DNA

AFM in situ DNA describes in situ analysis (or study) of DNA using atomic force microscopy. Discover the latest research on AFM in situ DNA here.

ALS

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS & FTD: TDP-43

ALS shares with a considerable proportion of FTD cases the same neuropathological substrate, namely, inclusions of abnormally phosphorylated protein tdp-43 (ptdp-43). Here are the latest discoveries pertaining to ptdp-43 and these diseases.

ALS - Pathogenic Mechanisms

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS - Phenotypes

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating phenotypes associated with this genetically heterogeneous disorder.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here are the latest discoveries pertaining to this disease.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS therapies here.

ALS: Transposon de-silencing

Transposon silencing is a form of transcriptional gene silencing. These gene silencing mechanisms are impaired in Amyotrophic lateral sclerosis (ALS). Here are the latest discoveries pertaining to transposon silencing and this disease.

© 2020 Meta ULC. All rights reserved
/feed-previews/parkinsons-disease-diagnostics-and-clinical/6034e3fd-2763-4cbc-860f-f5877e3d6425